SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to a government-backed funding initiative, fueling intense debate between bulls anticipating a potential short squeeze and skeptics raising concerns over extreme valuations and dilution. The stock's volatile price action has triggered widespread community discussion regarding the sustainability of the rally and the impact of the newly announced capital injection on future growth.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing heightened investor attention following a positive fireside chat at the CIBC Technology & Innovation Conference, where leadership highlighted profitable growth and a strong backlog in the QNX and secure communications divisions. The community is actively discussing the company's evolving role in the physical AI and robotics sectors, with many investors debating the long-term potential of the QNX operating system as a foundational element in high-performance edge computing.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is rallying as investors react to a government initiative providing federal funding and equity stakes to support the development of quantum technology. The community is heavily focused on the stock's high short interest and the potential for a significant squeeze, while debates persist regarding the firm's long-term commercial scalability and the impact of the newly announced government support.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Akari Therapeutics

Akari Therapeutics is surging following positive preclinical data for its lead ADC program, AKTX-101, which demonstrated synergistic potential in treating KRAS-mutated pancreatic cancer. The community is actively discussing the stock's significant momentum and low-float volatility, with traders closely monitoring volume sustainability and key resistance levels as the company advances its oncology pipeline.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings Corp is seeing a massive surge in volume and investor interest as community members highlight its KARNO power module as a critical solution for AI data centers requiring native 800-volt DC efficiency. Sentiment is buoyed by speculative excitement regarding military and space-sector partnerships, though a vocal contingent of traders is actively warning of potential volatility and dilution risks following the rapid rally.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending ahead of its quarterly earnings release as investors weigh aggressive expansion into hotel bookings and delivery against competitive concerns in the autonomous vehicle sector. The community is actively debating the company's valuation and the potential for long-term growth versus persistent short-term price stagnation.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is seeing intense community debate driven by anticipation of upcoming earnings and potential reactions to shareholder meeting votes, particularly regarding authorization for reverse splits. Investors are closely monitoring prescription growth and GPO agreement impacts on commercial reach, while conflicting narratives between bullish expectations for the Tonmya launch and bearish concerns over cash burn and dilution continue to fuel heavy social media engagement.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a major sector-wide catalyst involving the U.S. government's announcement of a multi-billion dollar quantum computing initiative. The community is actively debating the implications of IonQ's exclusion from this specific funding round, while long-term bulls argue its independent financial strength and strategic acquisitions solidify its position as a sector leader.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is trending due to a private placement investment aimed at accelerating its STARLAUNCH platform, drawing intense community debate over its potential as a 'space sector' play. Investors remain deeply divided, with some betting on institutional accumulation and the upcoming SpaceX IPO as catalysts, while others warn of significant cash burn, potential dilution, and concerns regarding corporate governance and executive turnover.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is seeing intense debate as investors weigh strong year-over-year growth in user assets and trading volume against a recent uptick in operating expenses and net losses. While some community members are accumulating shares in anticipation of the upcoming removal of day trading restrictions and active buyback programs, others remain skeptical, citing continued spending pressure and historical price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial...

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) will be releasing its Q2 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-enanta-pharmaceuticals-inc-stock...

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven ha...

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving Average   - Here's Why

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Above 50 Day Moving Average - Should You Sell...

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data...

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Current Price	$14.27
Prev Close	$13.83
Open	$13.72
Dividend Yield	0.00%
50-Day Moving Average	$13.60
Beta	1.07
Avg. Volume	118,774.85
PE Ratio	-5.33

52-Week High	$17.15
52-Week Low	$5.55
Market Capitalization	$402.15M
EPS (Annual)	-$3.84
Price to Book	3.45
Revenue Per Employee	$544,366.67

ENTA
Enanta Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ENTA News

ENTAEnanta Pharmaceuticals Inc